LILLE, France & PARIS--(BUSINESS WIRE)--4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors..

法国里尔和巴黎——（商业新闻短讯）——4P Pharma是一家总部位于里尔的临床阶段创业工作室，专注于开发未经治疗的严重疾病的治疗方法，宣布在私人投资者的参与下，该公司在第二次收盘时成功获得了1500万欧元的总资本。

With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.

有了这笔资金，4P Pharma的股东们再次对该公司针对未经治疗的严重疾病的药物再生模式充满信心。他们欢迎两家4P制药公司的SPV进入第二阶段临床开发，这是该公司商业模式强大潜力的基础。

Revital Rattenbach, CEO of 4P-Pharma: 'As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases.'.

4P Pharma首席执行官RevitalRattenbach：“作为4P Pharma首席执行官，我很高兴我们的投资者年复一年地重新信任我们的科学和发展方法。这一财政支持突显了我们在过去十年中取得的重大进展。它证明了我们为未经治疗的严重疾病患者提供一流治疗的模式的优势。”

This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.

这一额外股东的财务支持将使4P Pharma能够部署其药物再生模型，该模型由已建立的MOA与未探索的疾病生物学靶向之间的未公开匹配引发，为开发一流疗法铺平了道路。

This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.

这一现金流储备确保了财务稳定性和运营灵活性，通过并购和许可积极参与外部增长机会，并加速4P Pharma的初创工作室模式，以建立通往商业阶段的平衡管道。

Revital Rattenbach concludes: 'After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community.'.

RevitalRattenbach总结道：“经过十年的发展，4P制药正在开启一个新的增长转折点。这一成功的资金保障将使我们能够推进以患者为中心的愿景，将科学转化为成功案例，为患者和整个医学界带来最大利益。”

About 4P-Pharma

关于4P Pharma

Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property.

4P Pharma成立于2014年，是一家总部位于里尔的临床阶段生物技术公司，致力于为未满足医疗需求的严重疾病开发创新的治疗方法。我们的目标是迅速为患者提供一流的药物。4P Pharma利用开发时间缩短的候选药物，部分原因是具有强大知识产权的监管机会（紧急使用或有条件的市场授权）。

The company is headquartered in Lille and Paris and has over 20 employees..

该公司总部位于里尔和巴黎，拥有20多名员工。